ALNY Financial Facts
Net loss per common share - basic and diluted: -1.05Net loss: -90.13M
See Full Income Statement
Commitments and contingencies (Notes 4, 5 and 6): 0
Total liabilities and stockholders' equity: 1.38B
See Full Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings
|
Expand Research on ALNY
| Next EPS Date | 7/30/26 | EPS Growth Rate | +409.4% |
|---|---|---|---|
| Average EPS % Beat Rate | +183.9% | Revenue Growth Rate | +70.6% |
| Average % Move 1-Wk after EPS | +5.0% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
7/30/26  |
Q226 | N/A | $1.63 | N/A | N/A | $1.32B | = | N/A | N/A | ||
| 4/30/26 | Q126 | $1.99 | $0.91 | +$1.08 | $1.17B | $1.12B | = |  | | Details | |
| 2/12/26 | Q425 | $1.25 | $1.19 | +$0.06 | $1.1B | $1.15B | = | | | Details | |
| 10/30/25 | Q325 | $2.90 | $0.52 | +$2.38 | $1.25B | $946.73M | = | | | Details | |
| 7/31/25 | Q225 | $0.32 | -$0.59 | +$0.91 | $773.69M | $643.2M | = | | | Details | |
| 5/1/25 | Q125 | -$0.01 | -$0.93 | +$0.92 | $594.19M | $588.75M | = | | | Details | |
| 2/13/25 | Q424 | $0.06 | -$0.58 | +$0.64 | $593.16M | $580.61M | = | | | Details | |
| 10/31/24 | Q324 | -$0.50 | -$0.93 | +$0.43 | $500.92M | $532.36M | = | | | Details |
